CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University)

N/A

Report date: 2022/09/01 20:01:19

Base Information

Drug NameCD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou UniversityThe First Affiliated Hospital Of Soochow University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Soochow University
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A